Akebia Therapeutics, Inc.
AKBA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001517022
No open-market purchases or sales by Akebia Therapeutics, Inc. insiders were filed in the last 90 days; 170 institutions reported holding it in 13F filings for Q2 2026, worth $123.2M in total; no superinvestor holds it.
Q3 2025 vs. Q2 2025
How the institutions holding Akebia Therapeutics, Inc. changed between Q2 2025 and Q3 2025.
All holders in Q3 2025All holders in Q2 2025
| Measure | Q2 2025 | Of which not filed for Q3 2025 | Q3 2025 | Change |
|---|---|---|---|---|
| Holders | 158 | 2 | 177 | +21 |
| Shares | 108.3M | 59.1K | 123.7M | +15.5M (+14.3%) |
| Value | $394.1M | $215.0K | $337.7M | −$56.2M (−14.3%) |
2 institutions that held it in Q2 2025 haven't filed for Q3 2025 yet. Not filing isn't selling, so the changes leave them out.
New holders (39)
Institutions that held Akebia Therapeutics, Inc. at the end of Q3 2025 but not at the end of Q2 2025.
Sold out (18)
Institutions that held Akebia Therapeutics, Inc. at the end of Q2 2025 and filed for Q3 2025 without it.
| Institution | Shares, Q2 2025 | Value, Q2 2025 |
|---|---|---|
| Great Point Partners LLC | 1,985,915 | $7.23M |
| EAM Investors, LLC | 1,454,328 | $5.29M |
| Woodline Partners LP | 1,001,360 | $3.64M |
| ExodusPoint Capital Management, LP | 289,528 | $1.05M |
| Longaeva Partners L.P. | 191,691 | $697.8K |
| Cubist Systematic Strategies, LLC | 168,738 | $614.2K |
| Point72 Asset Management, L.P. | 93,721 | $341.1K |
| Fred Alger Management, LLC | 67,013 | $243.9K |
| Y-Intercept (Hong Kong) Ltd | 30,657 | $111.6K |
| HSBC Holdings PLC | 28,309 | $104.5K |
| Public Employees Retirement System of Ohio | 27,200 | $99.0K |
| US Bancorp | 16,121 | $58.7K |
| Balyasny Asset Management LLC | 9,154 | $33.3K |
| Ameliora Wealth Management Ltd. | 5,615 | $20.4K |
| Fifth Third Bancorp | 3,300 | $12.0K |
| Headlands Technologies LLC | 1,254 | $4.57K |
| Ameritas Advisory Services, LLC | 437 | $1.59K |
| Stephens Consulting, LLC | 6 | $22 |
Not filed for Q3 2025 yet (2)
Institutions that held Akebia Therapeutics, Inc. at the end of Q2 2025 and haven't filed a 13F for Q3 2025. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2025 | Value, Q2 2025 |
|---|---|---|
| CIBC World Markets Corp | 30,804 | $112.1K |
| E Fund Management Co., Ltd. | 28,273 | $102.9K |